Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Fintel reports that on May 13, 2025, JP Morgan downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

TerraVest Industries Inc (TVK.T) is expected to report for 2Q. United Homes Group Inc (UHG) is expected to report for 1Q. Valeura Energy Inc (PNWRF,VLE.T) is expected to report for 1Q. Vislink ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

British stocks ended mixed on Tuesday, as investors assessed a tick up in U.S. inflation data, while signs of a cooling UK ...